Grace Therapeutics GRCE
NASDAQ GRCE
$1.75 -0.06 (-3.31%)
At close: Nov 16, 2026 · 4:00 PM EST

Grace Therapeutics (GRCE) Asset Writedowns and Impairment (2017 - 2026)

Updated

Analysis

Grace Therapeutics (GRCE) Asset Writedowns and Impairment (2017 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn
5 Novartis Ag 310.90 Bn 284.14 Bn -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn
10 Grace Therapeutics 35.10 Mn -35.61 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 13.53 Mn
Mar 31, 2024 -32,000.00
Sep 30, 2023 19,000.00
Jun 30, 2023 13,000.00
Mar 31, 2023 28.65 Mn
Sep 30, 2022 31,000.00
Mar 31, 2022 -249,000.00
Mar 31, 2021 -3.71 Mn
Sep 30, 2020 3.71 Mn
Feb 28, 2017 505,427.90
API Access

Grace Therapeutics Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=GRCE&period=max&api_key=YOUR_API_KEY